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Siglec-E retards atherosclerosis by inhibiting 
CD36-mediated foam cell formation
Yaw‑Wen Hsu1, Fu‑Fei Hsu1, Ming‑Tsai Chiang1, Dong‑Lin Tsai1, Fu‑An Li1, Takashi Angata2, Paul R. Crocker3 
and Lee‑Young Chau1* 
Abstract 
Background: The accumulation of lipid‑laden macrophages, foam cells, within sub‑endothelial intima is a key 
feature of early atherosclerosis. Siglec‑E, a mouse orthologue of human Siglec‑9, is a sialic acid binding lectin pre‑
dominantly expressed on the surface of myeloid cells to transduce inhibitory signal via recruitment of SH2‑domain 
containing protein tyrosine phosphatase SHP‑1/2 upon binding to its sialoglycan ligands. Whether Siglec‑E expression 
on macrophages impacts foam cell formation and atherosclerosis remains to be established.
Methods: ApoE‑deficient  (apoE−/−) and apoE/Siglec‑E‑double deficient  (apoE−/−/Siglec‑E−/−) mice were placed on 
high fat diet for 3 months and their lipid profiles and severities of atherosclerosis were assessed. Modified low‑density 
lipoprotein (LDL) uptake and foam cell formation in wild type (WT) and Siglec‑E−/−‑ peritoneal macrophages were 
examined in vitro. Potential Siglec‑E‑interacting proteins were identified by proximity labeling in conjunction with 
proteomic analysis and confirmed by coimmunoprecipitation experiment. Impacts of Siglec‑E expression and cell 
surface sialic acid status on oxidized LDL uptake and signaling involved were examined by biochemical assays.
Results: Here we show that genetic deletion of Siglec‑E accelerated atherosclerosis without affecting lipid profile in 
 apoE−/− mice. Siglec‑E deficiency promotes foam cell formation by enhancing acetylated and oxidized LDL uptake 
without affecting cholesterol efflux in macrophages in vitro. By performing proximity labeling and proteomic analy‑
sis, we identified scavenger receptor CD36 as a cell surface protein interacting with Siglec‑E. Further experiments 
performed in HEK293T cells transiently overexpressing Siglec‑E and CD36 and peritoneal macrophages demonstrated 
that depletion of cell surface sialic acids by treatment with sialyltransferase inhibitor or sialidase did not affect interac‑
tion between Siglec‑E and CD36 but retarded Siglec‑E‑mediated inhibition on oxidized LDL uptake. Subsequent 
experiments revealed that oxidized LDL induced transient Siglec‑E tyrosine phosphorylation and recruitment of SHP‑1 
phosphatase in macrophages. VAV, a downstream effector implicated in CD36‑mediated oxidized LDL uptake, was 
shown to interact with SHP‑1 following oxidized LDL treatment. Moreover, oxidized LDL‑induced VAV phosphorylation 
was substantially lower in WT macrophages comparing to Siglec‑E−/− counterparts.
Conclusions: These data support the protective role of Siglec‑E in atherosclerosis. Mechanistically, Siglec‑E interacts 
with CD36 to suppress downstream VAV signaling involved in modified LDL uptake.
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Background
Atherosclerosis is the underlying cause of most car-
diovascular diseases, including coronary heart disease, 
stroke, and peripheral vascular disease [1]. It is a complex 
pathological process initiated by the injury and activa-
tion of endothelium caused by hypercholesterolemia and 
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other risk factors, followed by the accumulation and oxi-
dative modification of low-density lipoproteins (LDLs) 
and the recruitment of circulating inflammatory cells, 
including monocytes and T lymphocytes, to the suben-
dothelial intima [2–4]. The monocytes then differentiate 
into macrophages and uptake modified LDLs to become 
foam cells with a feature of intracellular cholesterol accu-
mulation as lipid droplets, which is the hallmark of early 
lesion [2–4]. These foam cells in turn produce more 
inflammatory cytokines and growth factors to promote 
the migration of the quiescent vascular smooth muscle 
cells (VSMCs) in the medial layer to intima and activate 
VSMC proliferation and increased synthesis of extracel-
lular matrix proteins, resulting in the thickening of intima 
and occlusion of the blood vessel [2–4]. At the advanced 
stage foam cells are unable to fully process the internal-
ized cholesterol and eventually die, causing the depo-
sition of cholesterol and the formation of lipid necrotic 
core in the arterial wall. This triggers further immune 
reaction to exacerbate the disease progression and pro-
voke coronary rupture underlying heart attack [2–4]. It is 
apparent that macrophage-derived foam cells play a key 
role in the initiation and progression of atherosclerosis.
Siglecs are a family of sialic acid-binding immuno-
globulin-like receptors predominantly expressed on cells 
of immune system to regulate their functions through 
recognizing their glycan ligands [5]. The cytoplasmic 
domains of most Siglecs contain the immunoreceptor 
tyrosine-based inhibitory motifs (ITIMS) which trans-
duce negative signals via recruitment of SH2-domain 
containing protein tyrosine phosphatases, such as Src 
homology region 2 domain-containing phosphatase-1 
(SHP-1) and SHP-2. Human Siglec-9 and its murine 
orthologue, Siglec-E, are mainly expressed on cells of the 
myeloid lineage, including neutrophils, monocytes/mac-
rophages, and dendritic cells. Earlier studies have shown 
that overexpression of Siglec-9 enhances interleukin-10 
(IL-10) but reduces tumor necrosis factor-α (TNF-α) 
production in macrophages [6]. It has been shown that 
ligands for Siglec-9 are up-regulated in human tumor 
samples and that tumor Siglec-9 ligands inhibit neutro-
phil activation in vitro, indicating that Siglec-9 is impli-
cated in innate immune response to cancer [7]. Moreover, 
studies on Siglec-E-knockout mice have revealed that 
Siglec-E is a negative regulator of neutrophil recruit-
ment to the inflammatory lung via suppressing CD11b 
β2-integrin-dependent signaling [8]. A recent study has 
also suggested that Siglec-E deficiency accelerates aging 
process in mice by modulating oxidative stress [9]. These 
findings highlight the importance of Siglec-9/E in the reg-
ulation of immune and inflammatory reactions in health 
and diseases. Nevertheless, the role of Siglec-9/E in vas-
cular disease has not yet been explored. In an attempt to 
explore the role of Siglec-9/E in atherosclerosis, we gen-
erated apoE/Siglec-E double deficient  (apoE−/−/SE−/−) 
mice to assess the effect of Siglec-E deletion on  apoE−/− 
mice, which is a mouse model developing hypercholes-
terolemia and atherosclerotic lesions similar to those in 
humans [10]. We show that Siglec-E deficiency facili-
tates vascular lesion formation in  apoE−/− mice. At the 
cellular level, Siglec-E inhibited foam cell formation via 




N-terminal Flag tagged mouse CD36 plasmid (Flag-
CD36) and N-terminal HA-tagged human CD36 plas-
mid (HA-CD36) were obtained from Sino Biological Inc. 
(Wayne, PA, USA). C-terminal Myc-Flag-tagged Siglec-9 
plasmid (Flag-Siglec-9) was from OriGene (Rockville, 
MD, USA). The C-terminal HA-tagged wild type (WT) 
Siglec-E construct (HA-SE) was prepared by polymerase 
chain reaction (PCR) amplification of full length Siglec-
E coding sequence from mouse spleen cDNAs using the 
following primers: 5′-AGA ATT CAT GCT GCT GTT GCT 
GCT GCT-3′ and 5′-CCT CGA GTC AAG CGT AAT CTG 
GAA CAT CGT ATG GGT ATG GCC ATG CGG TCCT-3′. 
The PCR product with HA-tag sequence fused to C-ter-
minus of Siglec-E was digested with EcoRI and XhoI 
restriction enzymes and subcloned into pcDNA3 vector 
(Invitrogen, Waltham, MA, USA). The sialic acid bind-
ing defective mutant of Siglec-E (Siglec-ER126D) [8] with 
HA-tag was generated by site-directed mutagenesis using 
PCR.
Animals
WT and Siglec-E−/−  (SE−/−) mice in C57BL/6 genetic 
background [8] were obtained from intercross between 
Siglec-E heterozygous  (SE±) mice. To generate 
 ApoE−/−SE−/− mice,  ApoE−/− mice on C57BL/6  J back-
ground, which were originally obtained from Jackson 
laboratory (Bar Harbor, ME, USA) and maintained in our 
animal facility, were crossbred with  SE−/− mice to gen-
erate  ApoE±/SE± mice, which were backcrossed with 
 apoE−/− mice to produce  ApoE−/−/SE± mice. These mice 
were then intercrossed to generate  ApoE−/− mice bearing 
 SE+/+, SE ±, and  SE−/− genotypes. To facilitate atheroscle-
rotic lesion formation,  ApoE−/− and  ApoE−/−SE−/− mice 
at age of 8 to10-week old were placed on high-fat diet 
(HFD) (D12108Ci; Research Diets Inc. New Brunswick, 
NJ, USA) with 1.25% cholesterol and 40% fat kcal for 
12 weeks. Mice were housed at ambient temperature of 
21–23 °C and on a 12 h light–dark cycle with free access 
to food and water in specific pathogen-free condition. 
One week before sacrifice, blood samples were collected 
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from animals. Serum high-density lipoprotein (HDL) 
and LDL separation was performed using HDL and LDL/
VLDL cholesterol assay kit (ab65390; abcam, Cambridge, 
MA, USA). The levels of total cholesterol, HDL and LDL 
were measured by Infinity Cholesterol Reagent (401-
100P; Sigma, St Louis, MO, USA). The serum triglycer-
ide level was measured by dry chemistry analyzer Fuji 
Dri-Chem 4000i using FUJI DRI-CHEM SLIDE TG-PIII 
(Fujifilm Corporation, Tokyo, Japan). After animals were 
sacrificed, heart and aorta were removed from phos-
phate-buffered saline (PBS)-perfused animals, fixed in 4% 
paraformaldehyde.
Pathological assessment
The thoracic-abdominal aortas were subjected to en face 
oil red dye (ORD)-staining and the luminal surface visu-
alized by stereoscopic microscopy (SteREO Lumar V12; 
ZEISS, Hamburg, Germany). The images were analyzed 
by MetaMorph (7.7.5.0) software. Hearts were embedded 
in paraffin and sectioned at 5 um for histological exami-
nation and immunostaining. Total 40 serial sections from 
aortic sinus of each mouse were collected, and 5 sections 
sampled from every 10 consecutive sections were sub-
jected to Trichrome staining with aniline blue (Sigma). 
To perform immunohistochemistry, sections were sub-
jected to antigen retrieval in 10  mM Na-citrate pH 6.0 
containing 0.05% Tween-20 at 98 °C for 20 min, followed 
by blocking with 5% donkey serum in PBS containing 
0.2% Triton X-100 for 3 h at room temperature. Sections 
were then treated with 3%  H2O2 to exhaust endogenous 
peroxidase activity, and incubated with control rat IgG 
(sc-2026, Santa Cruz, Dallas, TX, USA) or rat anti-F4/80 
antibody (GTX26640, Genetex, Irvine, CA, USA) as indi-
cated in PBS at 4  °C overnight. After three PBS washes, 
sections were incubated with horseradish peroxidase 
conjugated secondary antibody and the antigen–anti-
body complex was visualized by a 3′-diaminobenzidine 
liquid substrate system (Sigma). For quantitative analysis, 
the images were captured by Pannoramic 250 FLASH II 
Slide Scanner (3D-Histech®, Budapest, Hungary). The 
areas with F4/80+-macrophages, lesion sizes and per-
centages of necrotic core were quantified by MetaMorph 
(7.7.5.0) software.
Peritoneal macrophage isolation
Peritoneal macrophages were isolated accordingly [11]. 
Briefly, mice were intraperitoneally injected with 1.5  ml 
of 3% thioglycollate (1.08191.0500, Merck, Kenilworth, 
NJ, USA). After 4  days, peritoneal macrophages were 
isolated by washing the peritoneal cavity with F12/Dul-
becco’s modified Eagle medium (F12/DMEM) containing 
0.5% bovine serum albumin (BSA). Cells were then plated 
on culture plate or cover slips in medium containing 
10% fetal bovine serum (FBS). After 4 h incubation, the 
nonadherent cells were removed and the adherent cells 
used as peritoneal macrophages. Unless specified, mac-
rophages pooled from 3 mice of each genotype were used 
for comparative experiments.
Real‑time quantitative PCR
Total RNAs were extracted from peritoneal macrophages 
isolated from  ApoE−/− and  ApoE−/−SE−/− mice fed with 
HFD for 12 weeks using TRIzol reagent (Thermo Fisher 
Scientific, Waltham, MA, USA), followed by reverse-
transcription using the Superscript III first strand cDNA 
synthesis kit  (Thermo Fisher Scientific). Real-time PCR 
was performed using a LightCycler® FastStart DNA 
MasterPLUS SYBR Green I kit (Roche Applied Science, 
Upper Bavaria, Germany) on a LightCycler® Carousel-
Based System (Roche Applied Science). The primer 
sequences used for PCR are listed as follows: TNFα (5′-
AGA CCC TCA CAC TCAGA-3′ and 5′-CCT TGT CCC 
TTG AAG AGA AC-3′), IL-6 (5′-GAG GAT ACC ACT CCC 
AAC AGACC-3′ and 5′-AAG TGC ATC ATC GTT GTT 
CAT ACA -3′), MCP-1 (5′-CTT CTG GGC CTG CTG TTC 
A-3′ and 5′-CCA GCC TAC TCA TTG GGA TCA-3′), IL-10 
(5′-GGT TGC CAA GCC TTA TCG GA-3′ and 5′-ACC 
TGC TCC ACT GCC TTG CT-3′), and IL-1β (5′-GAT CCA 
CAC TCT CCA GCT GCA-3′ and 5′- CAA CCA ACA AGT 
GAT ATT CTC CAT G-3′). GAPDH (5′-TGA AGG TCG 
GTG TGA ACG GAT TTG -3′ and 5′- TCT CGT GGT TCA 
CAC CCA TCA CAA -3′) was used as an internal control 
for normalization.
Modified LDL preparation
To prepare acetylated LDL (acLDL), 1 mg of human LDL 
(360–10, Lee BioSolution, Maryland Heights, MO, USA) 
in 1  ml of 50% ice-cold saturated sodium acetate was 
incubated with 1.5 μl of acetic anhydride for 1 h at 4 °C 
with rotation [12]. The acLDL was then dialyzed against 
PBS containing 300 µM ethylenediaminetetraacetic acid 
(EDTA) and once more against PBS at 4  °C. To prepare 
1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate (Dil)-labeled acLDL (Dil-acLDL), 1  ml of 
acLDL was incubated with 50  µl Dil-dye (3  mg/ml) in 
PBS at 37  °C for 18  h, followed by ultrafiltration using 
Microcon centrifugal filter (MRCF0R030, Merck Mil-
lipore, Darmstadt, Germany) against PBS to remove 
unbound Dil-dye. To prepare oxidized LDL (oxLDL), 
LDL (2 mg/ml) in PBS was incubated with 10 µM  CuSO4 
for 18 h at 37 °C [13]. Oxidation was stopped by adding 
20 µM butylated hydroxytoluene and 300 µM EDTA. For 
Dil-oxLDL preparation, Dil-LDL was first prepared by 
incubation with Dil-dye as described above, followed by 
CuSO4 oxidation.
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Modified LDL binding and uptake
The binding and uptake of modified LDL were performed 
as described [14]. Macrophages plated on 48-well plates 
or glass coverslips were incubated with 10 µg/ml of Dil-
acLDL or Dil oxLDL as indicated at 4 °C or 37 °C for indi-
cated times. After 3 washes with Hank’s balanced saline 
solution (HBSS), cells were fixed and fluorescence were 
examined by confocal microscope and images analyzed 
by MetaMorph (7.7.5.0). To examine the effect of desia-
lylation, macrophages were treated with 0.1 unit/ml of 
Arthrobacter ureafaciens sialidase (24229-74, Nacalai 
Tesque, Kyoto, Japan) in HBSS at 37 °C for 30 min prior 
to assay. In separate experiment, macrophages were pre-
treated with 10  µM of NSC87877, a potent inhibitor of 
SHP-1/2 phosphatase [15], for 30  min in culture before 
assay. To perform assay with HEK293T cells overexpress-
ing HA-SE together with or without Flag-CD36, cells 
were incubated with 5  µg/ml of Dil-oxLDL at 37  °C for 
1  h and examined by confocal microscopy as described 
above.
Foam cell formation
Macrophages plated on 12-well plates were incubated 
with 50  µg/ml of acLDL or oxLDL for 24  h in culture. 
Cells were then fixed with 4% paraformaldehyde and 
stained with ORD [14].
Cholesterol Efflux
Cholesterol efflux was determined using the cholesterol 
efflux fluorometric Assay Kit (Cat. K582100; BioVision, 
Milpitas, CA, USA). Briefly, macrophages were plated 
on 96-well plates  (1X105 /well) and labeled with fluores-
cently-labeled cholesterol analogue for 1 h. After equili-
bration in culture for 16 h, cells were incubated without 
(negative control) or with 10 mM methyl-β cyclodextrin 
(positive control) or 50 μg/ml human HDL(MBS173147, 
MyBioSource, San Diego, CA, USA) as indicated in phe-
nol red-free, serum-free RPMI medium for 6 h. The cul-
ture medium and cell lysate were separately collected and 
the fluorescence intensity (RFU) was determined using a 
microplate reader (SpectraMax Gemini EM Microplate 
Reader, Molecular Devices, San Jose, CA, USA). The per-
centage of cholesterol efflux = [RFU of medium/(RFU of 
cell lysate + RFU of medium)] × 100.
SILAC (Stable isotope labeling using amino acids in cell 
culture) labeling of Raw264.7 cells
Murine Raw264.7 cell line originally obtained from 
American Type Culture Collection (ATCC, Gaithersburg, 
MD, USA) was maintained in DMEM supplemented with 
10% FBS, 100 units/ml penicillin, and 100 μg/ml strepto-
mycin. To perform SILAC labeling, cells were cultured 
in DMEM growth medium supplemented with light 
(L) isotope-labeled 12C6-lysine/ 12C6 14N4-arginine and 
heavy (H) isotope-labeled 13C6-lysine/ 13C6 15N4-arginine 
(Thermo Fisher Scientific), respectively, for 6 passages. 
L- and H-labeled cells were maintained in the same 
growth medium according to the instruction provided by 
manufacturer.
Proximity labeling of putative Siglec‑E ligands
To perform proximity labeling [16], 10  µg of human 
immunoglobulin G-Fc fragment (AG714, Merck Milli-
pore) or recombinant Siglec-E with a C-terminal human 
IgG1-Fc tag (Siglec-E-Fc fusion protein) (551506, Bioleg-
end, San Diego, CA, USA) was pre-incubated with 10 µg 
of horse peroxidase (HRP)-conjugated anti-Fc antibody 
at 4  °C for 30  min to form complex. Equal amounts of 
L- and H-isotope labeled Raw264.7 cells (2 × 107) were 
then harvested, washed twice with PBS, and resuspended 
in 1 ml of HBSS containing HRP-Fc complex and HRP-
Siglec-E complex, respectively. After incubation at 4  °C 
for 1  h with rotation, cells were washed twice with ice-
cold HBSS and incubated with 10  µM biotin tyramide 
(SML2135, Sigma) and 10 mM  H2O2 in 1 ml of 20 mM 
Tris–HCl pH 8.0 buffer containing 140 mM NaCl (TBS) 
at room temperature for 10 min. Cells were then washed 
3 times with ice-cold TBS buffer, followed by lysed in 
0.5 ml of RIPA buffer containing protease inhibitor cock-
tails. After centrifugation at 14,000 xg at 4 °C for 15 min, 
four hundred µl of supernatant (cell lysate) from each 
L and H-labeled cells were mixed and incubated with 
400 µl of streptavidin-conjugated magnetic beads (88816, 
Thermo Fisher Scientific) at 4  °C for 2  h with rotation. 
After washing extensively with RIPA buffer, bound pro-
teins were eluted by 2 × sodium dodecyl sulfate (SDS)-
sample buffer. Biotinylated proteins were examined by 
SDS–polyacrylamide gel electrophoresis (SDS-PAGE) 
and blotting with HRP-conjugated streptavidin (N100; 
Thermo Fisher Scientific).
Proteomic analysis of biotinylated proteins
The eluted biotinylated proteins were subjected to SDS-
PAGE with a short (0.5  cm) separating gel. Gel frag-
ment containing proteins were excised, followed by 
in-gel digestion with trypsin. The tryptic peptides were 
analyzed on a NanoLC/MS/MS system, which is com-
posed of a nanoUPLC (NanoACQUITY, Waters, Mil-
ford, MA,USA) and a high-resolution mass spectrometer 
(Orbitrap Elite, Thermo Fisher Scientific). The acquired 
MS raw data were further processed by Proteome Dis-
coverer (v2.2.0.388, Thermo Fisher Scientific) to retrieve 
the information of protein identification and relative 
abundance quantification.
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Transient transfection
HEK293T cells originally obtained from ATCC were 
cultured in DMEM supplemented with 10% FBS, 100 
units/ml penicillin, and 100  μg/ml streptomycin. Cells 
were transfected with HA-SE or Flag-CD36 vector alone, 
WT HA-SE or HA-SE mutant construct (Siglec-ER126D) 
together with Flag. CD36 construct for 24 h using Gen-
Jet™ plus transfection reagent (SL100499, SignaGen. 
Laboratories, Rockville, MD, USA) according to manu-
facturer’s instruction. To test the effect of sialyltransferase 
inhibitor, cells were treated with 200  µM of P-3FAX-
Neu5Ac (117405-58-0, Tocris, Ellisville, MO, USA) at 6 h 
post transfection, and harvested after 66  h incubation 
in culture. For sialidase treatment, cells transfected for 
48 h were rinsed with HBSS, followed by incubation with 
Arthrobacter ureafaciens sialidase as described above for 
macrophages prior to further experiment. In separate 
experiment, HEK293T cells were transfected with Flag-
Siglec-9 construct together with or without HA-CD36 
construct for 48  h, followed by treatment with sialidase 
for 30 min prior to harvest as described above.
Immunofluorescence confocal microscopy
HEK293T cells (1 × 105) transfected with FLAG-CD36 
together with HA-control, HA-SE, or HA-SE mutant vec-
tor as indicated for 24  h were reseeded on cell culture 
slide and incubated for additional 24 h. Cells were then 
fixed with 4% paraformaldehyde and permeabilized by 
0.2% saponin in PBS at room temperature for 10 min. Fol-
lowing incubation with 3% BSA and 5% goat serum (005–
000-121; Jackson ImmunoResearch, West Grove, PA, 
USA) in PBS at room temperature for 30 min, cells were 
incubated with rabbit anti-HA-tag (C29F4) (#3724S, Cell 
Signaling, Danvers, MA, USA) and mouse anti-FLAG M2 
(F1804; Sigma) antibodies together at room temperature 
for 1 h. A separate fixed cell slide incubated with control 
mouse and rabbit IgGs was served as a negative control. 
After 3 washes with PBS, cells were incubated with fluo-
rescein isothiocyanate –conjugated goat-anti mouse IgG 
(GTX26785; GeneTex) and Alexa Fluor 568-conjugated 
goat-anti-rabbit IgG (A-11011; Invitrogen) to detect 
FLAG- and HA-antigen–antibody complexes, respec-
tively. After nuclear stain by 4′,6-diamidino-2 phenylin-
dole, cells were visualized by confocal microscope (LSM 
510 META, ZEISS) using 63 × oil objective.
Immunoprecipitation and Western blot analysis
Cells were lysed in buffer containing 50  mM Tris–HCl 
pH 7.4, 150  mM NaCl, 50  mM NaF, 1  mM  Na3VO4, 
5 mM EDTA, 0.1% SDS, 1% Triton X-100, and protease 
inhibitor cocktails. Cell lysates were cleared by cen-
trifugation at 14,000 xg for 10  min at 4  °C. To perform 
immunoprecipitation of endogenous proteins, mac-
rophage cell lysates (~ 1 mg) were incubated with 10 µg 
of control IgG, anti-Siglec-E antibody (682802, Bioleg-
end) or anti-CD36 antibody (MF3, abcam) as indicated at 
4 °C for 18 h with rotation. Protein A/G-conjugated mag-
netic beads (#88803, Thermo Fisher Scientific) was then 
added, and incubation continued for additional 3  h at 
4 °C. Beads were collected and washed 3 times with lysis 
buffer, followed by elution of proteins bound to beads 
with 2 × SDS sample buffer. To perform immunoprecipi-
tation of Flag-CD36 overexpressed in HEK293T cells, cell 
lysates were prepared and ~ 400 μg of proteins was incu-
bated with 20 μl of anti-FLAG®M2 affinity resin (A2220, 
Sigma) for 2  h at 4  °C with rotation. Resin was then 
washed 4 times with the same lysis buffer and bound pro-
teins eluted using 2 × SDS sample buffer. To immunopre-
cipitate HA-SE or HA-CD36 overexpressed in HEK293T 
cells, anti-HA affinity resin (A2095, Sigma) was used as 
described above. To perform Western blot analysis of cell 
lysates and immunoprecipitated proteins, the following 
antibodies were used: anti-Siglec-E (AF5806, R&D, Min-
neapolis, MN, USA), anti-CD36 (AF2519, R&D), anti-
phosphoVAVY160 (MAB37861, R&D), anti-VAV antibody 
(sc8039, Santa Cruz), anti-SHP-1 (#3759, Cell Signaling), 
anti-HA (#2367S, Cell Signaling), anti-phospho-tyros-
ine antibody (#05–321, Merck Millipore), anti-GAPDH 
(GTX100118, Genetex), and anti-Flag M2 (F1804, Sigma) 
antibodies.
Lectin and streptavidin blotting
Cell lysates or immunoprecipitated CD36 were subjected 
to SDS-PAGE and transferred to poly(vinylidene fluoride 
membranes. After blocking with 2% BSA in PBS contain-
ing 0.05% Tween-20 (PBS-T), membranes were incu-
bated with biotin-labeled Sambucus nigra lectin (SNA) 
(B-1305, Vector Laboratories, Burlingame, CA, USA) 
and Maackia Amurensis Lectin II (MALII) (B-1265, Vec-
tor Laboratories), which bind to 2,6- and 2,3-linked sialic 
acids, respectively, in PBS containing 0.1  mM  CaCl2 at 
room temperature for 1 h. After 3 washes with PBS, the 
glycan-lectin complex was detected by HRP-conjugated 
streptavidin and enhanced chemiluminescence system 
(RPN2106; GE Healthcare, Uppsala, Sweden).
Statistical analysis
Quantitative data were presented as mean ± SE of at 
least 3 independent experiments. Statistical analysis 
was performed using  GraphPad Prism  software (v5.03). 
Statistical difference between two groups was assessed 
by Student’s t test. One-way ANOVA was used for data 
more than two groups. P < 0.05 was considered statisti-
cally significant.
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Results
Siglec‑E deficiency promotes foam cells and necrotic core 
in atherosclerotic lesion without affecting serum lipid 
profile in  apoE−/− mice
To assess the impact of Siglec-E expression on ath-
erosclerosis development, we generated  apoE−/− mice 
with Siglec-E gene deletion  (apoE−/−/SE−/− mice) for 
in  vivo studies. Both  apoE−/− and  apoE−/−/SE−/− mice 
(8–10  weeks old) were placed on HFD for 3  months to 
facilitate lesion formation and their serum lipid profiles 
were examined. As shown in Additional file 1: Figure S1, 
the increase of body weight and serum levels of triglyc-
eride, total cholesterol, LDL and HDL were comparable 
between these two groups of mice in both sexes. Ani-
mals were then sacrificed and the lesion formation in the 
aortic tissues examined by en face ORD staining, which 
detects the lipid deposition in the aortic wall. As illus-
trated in Fig. 1a, b, the ORD stained area was significantly 
larger in  apoE−/−/SE−/− mice compared to  apoE−/− mice 
irrespective of sex. The trichrome-stained advanced 
lesions developed in the aortic roots of these mice were 
also examined. As shown in Fig.  1c, d, the lesion sizes 
were comparable in  apoE−/− and  apoE−/−/SE−/− mice. 
Whereas the necrotic core was more prominent in the 
lesions of  apoE−/−/SE−/− mice. Likewise, more mac-
rophages identified by staining with F4/80 antibody were 
present in the lesions of  apoE−/−/SE−/− mice (Addi-
tional file 1: Figure S2a, b). To confirm the increased lipid 
accumulation in aortic lesions in  apoE−/−/SE−/−mice is 
resulted from enhanced foam cell formation, the perito-
neal macrophages were isolated from HFD-fed  apoE−/− 
and  apoE−/−/SE−/− mice and stained with ORD. As 
shown in Fig.  1e, more lipids had accumulated in mac-
rophages from  apoE−/−/SE−/− mice compared to  apoE−/− 
mice. An experiment was also performed to examine 
the inflammatory cytokine gene expression profile. As 
shown in Fig.  1f, the mRNA levels of pro-inflammatory 
cytokine TNF-α and IL-6 were significantly higher in 
 apoE−/−/SE−/− macrophages than  apoE−/− counterparts. 
The level of IL-1β mRNA was also moderately higher in 
 apoE−/−/SE−/− macrophages. No significant difference 
was observed for IL-10 and MCP-1 expressions between 
the two groups of cells.
Siglec‑E deficiency facilitates modified LDL uptake 
without affecting cholesterol efflux
To further assess the effect of Siglec-E on foam cell for-
mation, peritoneal macrophages isolated from WT and 
Fig. 1 Siglec‑E deficiency promotes foam cells and necrotic core in atherosclerotic lesion in  apoE−/− mice.  ApoE−/− and  apoE−/−/SE−/− mice were 
placed on HFD for 3 months. Heart and aortic tissues were harvested (a–d). a The representative images of oil‑red dye (ORD) stained aortic tissues. b 
The percentages of ORD stained areas in both groups of mice were quantified. c The representative images of Trichrome stained aortic root sections 
of male mice. d The lesion sizes and the percentages of lipid cores in the aortic roots were quantified. e Peritoneal macrophages isolated from 
HFD‑fed  apoE−/− and  apoE−/−/SE−/− mice were examined by ORD staining. f The mRNA expression levels of indicated cytokines in macrophages 
were examined by quantitative RT‑PCR
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 SE−/− mice were incubated with 50 µg/ml of acLDL or 
oxLDL in culture. After 24  h, the cholesterol accumu-
lation was examined by ORD staining. As illustrated 
in Fig.  2a, b, more foam cells were detected in  SE−/− 
macrophages than WT counterparts. Given that the 
level of intracellular cholesterol is influenced by the 
balance between modified LDL uptake and cholesterol 
efflux [17], we then performed experiments to examine 
the effect of Siglec-E on these two processes. We first 
examined whether Siglec-E affects the binding of modi-
fied LDL. When cells were incubated with 10 ug/ml 
of fluorescent dye-labeled Dil-acLDL or Dil-oxLDL at 
4 °C for 1 h, the quantities of Dil-labeled modified LDL 
bound on surfaces of both WT and  SE−/− macrophages 
were comparable (Additional file  1: Figure S3a, b), 
indicating that Siglec-E expression does not affect the 
binding of modified LDL to their surface receptors on 
macrophages. However, when the incubation was per-
formed at 37 °C, more Dil-labeled modified LDL accu-
mulated inside  SE−/− macrophages after 1 h incubation 
(Fig.  2c, d). We then performed a cholesterol efflux 
assay using a fluorescently-labeled cholesterol ana-
logue. As shown in Fig.  2e, the extents of cholesterol 
efflux induced by methyl-β-cyclodextrin as a positive 
control or HDL were comparable between WT and 
 SE−/− macrophages. Collectively, the results suggest 
that the inhibitory effect of Siglec-E on foam cell for-
mation is primarily through downregulating the uptake 
of modified LDL.
Identification of putative Siglec‑E ligands by proximity 
labeling method
Siglecs can interact with their sialoglycan ligands 
expressed on the same cells (cis-ligand) or other cells 
(trans-ligands). To explore the cellular mechanism 
Fig. 2 Siglec‑E deficiency facilitates modified LDL uptake without affecting cholesterol efflux. Peritoneal macrophages were isolated from WT and 
 SE−/− mice. a Macrophages were incubated with 50 µg/ml of oxLDL or acLDL as indicated for 24 h in culture. The accumulation of cholesterols was 
examined by ORD staining. b The quantitative results of ORD intensities. Data shown are the mean ± SE of 3 independent experiments. *P < 0.02 
vs WT. c Macrophages were incubated with 10 μg/ml of Dil‑oxLDL or Dil‑acLDL at 37 °C for indicated times. The amounts of uptake in each time 
point were quantified. Data shown are mean ± SE of 4 independent experiments. *P < 0.03 vs WT. d The representative images showing Dil‑oxLDL 
or Dil‑acLDL uptake after 1 h incubation. e Macrophages preloaded with fluorescently‑labeled cholesterol analogue were incubated without 
(negative) or with indicated agents for 6 h in culture. The percentage of fluorescence intensity in the medium was calculated. Results shown are the 
mean ± SE of 3 mice in each genotype
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underlying the effect of Siglec-E on foam cell forma-
tion, we adopted the proximity labeling method [16] 
to identify the putative Siglec-E ligands. As illustrated 
in Fig.  3a, we first labeled Raw264.7 cells, which are 
murine macrophage cell line, with light (L) and heavy 
(H) isotopes for 6 passages using SILAC-labeling tech-
nique, and then performed proximity labeling by incu-
bating the L- and H-labeled cells with Fc protein and 
Siglec-E-Fc fusion protein pre-bound with HRP-conju-
gated anti-Fc antibody, respectively. Equal amounts of 
cells were then mixed and cell lysate prepared for the 
subsequent isolation of biotinylated proteins. Strepta-
vidin blot analysis of the unmixed cell lysates clearly 
showed that more proteins were biotinylated in cells 
incubated with Siglec-E-Fc-HRP complex comparing 
to cells incubated with Fc-HRP control (Fig.  3b). The 
biotinylated proteins were then isolated and subjected 
to proteomic analysis. Several proteins with L/H ratio 
greater than 3.0 were identified as listed in Additional 
file  1: Table  S1. It was found that CD36, which is a 
class B scavenger receptor responsible for modified 
LDL uptake in macrophages [18], is one of the putative 
interacting proteins of Siglec-E. Three unique peptides 
of CD36 were identified for the quantitative analysis 
(Fig.  3c). The mass spectrum of an identified peptide 
was depicted in Fig. 3d.
Siglec‑E interacts with CD36 independent of sialic acid 
binding activity
To confirm whether Siglec-E interacts with CD36, we 
performed transient transfection experiment to express 
Flag-CD36 together with HA-SE or a HA-SE mutant 
lacking sialic acid binding activity (Siglec-ER126D) [8] 
in HEK293T cells. As revealed by confocal immuno-
fluorescence microscopy, both Flag-CD36 and HA-SE 
proteins were coexpressed on the surface of transfected 
HEK293T cells (Additional file  1: Figure S4). Experi-
ment was then performed to immunoprecipitate CD36 
protein using anti-Flag-affinity resin. When the immu-
noprecipitated proteins were subjected to Western blot 
analysis, the results showed that both WT and mutant 
HA-SE were coeluted with Flag-CD36, suggesting that 
sialic acid is not involved in the interaction between 
CD36 and Siglec-E (Fig.  4a). To further confirm this 
observation, we first examined the sialylation status of 
CD36 by performing lectin blotting. As demonstrated 
in Additional file  1: Figure S5, the binding signal of 
SNA to CD36 was much stronger than that of MALII, 
indicating that CD36 was predominantly modified by 
α 2, 6-linked sialylation. Treatment with 200  µM of 
P-3FAX-Neu5Ac, which is a cell permeable sialyltrans-
ferase inhibitor [19] for 66 h prior to immunoprecipita-
tion significantly reduced the extent of CD36 sialylation 
without affecting its interaction with HA-SE (Fig.  4b, 
c). Likewise, when HEK293T cells overexpressing both 
Fig. 3 Identification of putative Siglec‑E ligands by proximity labeling method. a Schematic overview of the procedure to identify Siglec‑E ligands. 
b Western blot analysis of biotinylated proteins in cell lysates and affinity‑purified fraction. c The list of identified CD36 peptides. Protein abundance 
ratio was calculated from the median of peptide ratios. d The Quantification Spectrum of selected peptide (EVVLEEGTTAFK) of CD36
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proteins were pretreated with Arthrobacter ureafa-
ciens sialidase (0.1 unit/ml) at 37 °C for 30 min prior to 
immunoprecipitation experiment, again it did not affect 
the interaction between Flag-CD36 and HA-SE (Fig. 4b, 
c). We also performed experiment with mouse perito-
neal macrophages to examine the interaction between 
endogenous CD36 and Siglec-E. Macrophages were 
pretreated with or without sialidase for 30 min prior to 
lysis. Cell lysates were then subjected to immunopre-
cipitation with control IgG or anti-Siglec-E antibody. 
As shown in Fig. 4d, CD36 was detected in the immu-
noprecipitates of Siglec-E from cells with or without 
sialidase treatment. When the immunoprecipitation 
was performed with anti-CD36 antibody, Siglec-E was 
detected in CD36 immunoprecipitate. Again, it was not 
affected by sialidase treatment as shown in the same 
figure. Together these results demonstrate that Siglec-
E interacts with CD36 independently of sialic acid. To 
examine whether similar phenomenon is observed with 
Siglec-9 and CD36, we performed transfection experi-
ment with Flag-Siglec-9 and HA-CD36 constructs in 
HEK293T cells for 48  h, followed by treatment with 
sialidase for 30 min as described above prior to immu-
noprecipitation with anti-HA tag affinity resin. Western 
blot analysis of the immunoprecipitates again revealed 
the interaction between Flag-Siglec-9 and HA-CD36 
independently of sialic acid (Additional file  1: Figure 
S6).
Sialic acid is involved in Siglec‑E‑mediated inhibition 
of oxLDL uptake by CD36
We then examined whether Siglec-E has an impact on 
CD36-mediated oxLDL uptake. To this end, HEK293T 
cells overexpressing Flag-CD36 alone or together with 
WT or mutant HA-SE were incubated with Dil-oxLDL 
(5  µg/ml) for 1  h. As shown in Fig.  5a, b, intracellular 
Dil-oxLDL accumulation was evident in cells overex-
pressing Flag-CD36 but not in cells overexpressing WT 
HA-SE. Notably, coexpression of WT but not mutant 
HA-SE significantly reduced Dil-oxLDL accumulation 
in Flag-CD36 overexpressing cells. The decrease in Flag-
CD-36-mediated Dil-oxLDL uptake was not due to the 
lower surface expression of Flag-CD36 in cells coexpress-
ing WT HA-SE (Additional file 1: Figure S4). When cells 
were pretreated with sialidase prior to incubation with 
Dil-oxLDL, Flag-CD36-mediated Dil-oxLDL uptake was 
markedly increased and not affected by the coexpres-
sion of WT or mutant HA-SE (Fig. 5a, b). The impact of 
desialylation on oxLDL uptake was also demonstrated in 
macrophages (Fig. 5c, d). Given that binding of Siglec-E 
Fig. 4 Siglec‑E interacts with CD36 independent of sialic acid binding activity. a HEK293 T cells were transfected with indicated vectors for 48 h. 
Cell lysates were prepared and subjected to immunoprecipitation with anti‑Flag affinity resin. The expressions of Flag‑CD36 and WT and mutant 
HA‑SE protein in whole cell lysates (WCL) and immunoprecipitates were examined by Western blot analysis with indicated antibodies. b, c HEK293T 
cells overexpressing Flag‑CD36 and WT HA‑SE were pretreated with P‑3FAX‑Neu5Ac for 66 h or with 0.1 unit/ml of sialidase for 30 min at 37 °C 
prior to immunoprecipitation with anti‑Flag affinity resin. Immunoprecipitates were then subjected to SNA lectin blotting (b) and Western blot 
analysis with indicated antibodies (c). d Peritoneal macrophages isolated from WT mice were treated without or with 0.1 unit/ml of sialidase for 
30 min at 37 °C. Cleared cell lysates were subjected to immunoprecipitation with control IgG, anti‑Siglec‑E or anti‑CD36 antibody as indicated. 
The immunoprecipitates were examined by Western blot analysis with indicated antibodies. The blots of immunoprecipitates were subjected to 
densitometry analysis and the relative quantitative results were shown under the blots. The value of control group for comparison in each blot was 
referred to 1
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with its sialoglycan ligands results in tyrosine phospho-
rylation of its ITIMS, which is crucial for subsequent 
recruitment of SHP-1/2 and transducing inhibitory sig-
nal [8, 9], we perform further experiment to explore the 
potential effect of modified LDL on Siglec-E activation. 
HEK293T cells overexpressing WT HA-SE alone, WT 
or mutant HA-SE together with Flag-CD36 as indicated 
were treated with oxLDL (50 µg/ml) for 30 min, and the 
level of phospho-tyrosine of HA-SE was assessed. As 
shown in Fig. 5e, oxLDL has no effect on the phosphoryl-
ation status of WT HA-SE expressed alone in HEK293T 
cells. When WT HA-SE-overexpressing cells were incu-
bated with Dil-oxLDL, there was no specific Dil-oxLDL 
binding on cell surface (Additional file 1: Figure S7), indi-
cating that oxLDL is not a ligand for HA-SE. However, 
oxLDL treatment enhanced tyrosine phosphorylation of 
WT but not mutant HA-SE in HEK293T cells coexpress-
ing Flag-CD36 (Fig.  5e). Moreover, sialidase pretreat-
ment reduced oxLDL-induced tyrosine phosphorylation 
of WT HA-SE (Additional file  1: Figure S8). When we 
performed the experiment with peritoneal macrophages, 
again oxLDL induced tyrosine phosphorylation of endog-
enous Siglec-E, which was abolished by sialidase pre-
treatment (Fig.  5f ). These data demonstrate that the 
binding of Siglec-E with its sialoglycan ligand following 
CD36-oxLDL interaction is essential for its negative reg-
ulation of CD36-mediated oxLDL uptake.
Siglec‑E downregulates CD36‑mediated signaling
We then assessed whether oxLDL-induced Siglec-E 
activation promotes the recruitment and activation of 
SHP-1 phosphatase to affect CD36 signaling. As shown 
in Fig.  6a, time course experiment demonstrated that 
oxLDL induced a transient Siglec-E tyrosine phospho-
rylation and interaction with SHP-1. Concurrently, 
oxLDL induced the phosphorylation of VAV, a guanine 
nucleotide exchange factor implicated in CD36-medi-
ated oxLDL uptake and foam cell formation [20, 21], in 
both WT and  SE−/− macrophages (Fig.  6b). Coimmu-
noprecipitation experiment again revealed the increase 
Fig. 5 Sialic acid is involved in Siglec‑E‑mediated inhibition of oxLDL uptake by CD36. a HEK293T cells transfected with indicated vectors for 
48 h were treated without or with sialidase (0.1 unit/ml) for 30 min at 37 °C, followed by incubation with Dil‑oxLDL (5 μg/ml) at 37 °C for 1 h. The 
intracellular accumulation of Dil‑oxLDL was examined by confocal microscopy. b The quantitative results of Dil‑oxLDL uptake in various groups of 
cells. Data shown are the mean ± SE of 3 independent experiments. *P < 0.05 vs cells overexpressing Flag‑CD36 alone. c Peritoneal macrophages 
were pretreated without or with sialidase, followed by incubation with Dil‑oxLDL as described above. Dil‑oxLDL uptake was examined by 
confocal microscopy. d The quantitative results of (c). Data shown are the mean ± SE of 3 independent experiments. *P < 0.01 vs untreated cells. e 
HEK293T cells transfected with indicated vectors were treated without or with oxLDL (50 μg/ml) for 30 min at 37 °C. Cell lysates were subjected to 
immunoprecipitation with anti‑HA tag affinity resin. The immunoprecipitates were then analyzed by Western blotting with anti‑phosphotyrosine 
and anti‑HA antibodies. The relative quantitative results were shown under the blot. f WT peritoneal macrophages were pretreated with or without 
sialidase, followed by incubation without or with oxLDL as described above. Cell lysates were prepared and immunoprecipitation was performed 
with anti‑Siglec‑E antibody. The immunoprecipitates were then analyzed by Western blotting with anti‑phosphotyrosine and anti‑Siglec‑E 
antibodies. The relative quantitative results were shown under the blot
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of interaction between VAV with SHP-1 following 
oxLDL treatment. Notably, the interaction between VAV 
and SHP-1 was more prominent in WT macrophages 
(Fig. 6c), which was correlated with lower phosphoryla-
tion of VAV in WT cells comparing to  SE−/− counter-
parts (Fig.  6b), supporting the negative regulation of 
CD36 downstream signaling by Siglec-E/SHP-1 axis. To 
further evaluate the effect of Siglec-E/SHP-1-mediated 
inhibitory signaling on oxLDL uptake, macrophages were 
pretreated with SHP-1 inhibitor NSC87877 [15] prior to 
incubation with Dil-oxLDL for 1 h. As shown in Fig. 6d, 
e, SHP-1 inhibition significantly increased Dil-oxLDL 
uptake in WT macrophages but not on SE-/- mac-
rophages. These findings support the notion that Siglec-
E suppresses oxLDL uptake and foam cell formation by 
attenuating CD36-induced downstream signaling in 
macrophages.
Discussion
Sialic acids have been implicated in several aspects of 
pathophysiology underlying atherosclerosis. Earlier stud-
ies have revealed the positive correlation between high 
plasma total sialic acids and the risk of coronary heart 
disease [22–24]. Moreover, the sialic acid content is lower 
in LDL isolated from patients with coronary heart dis-
ease [25]. The content of sialic acid is reduced in oxida-
tive modified LDL [26], and LDL de-sialylation results 
in more accumulation of lipid in cells [27]. These find-
ings suggest the potential involvement of sialic acid in 
the regulation of modified LDL uptake and cholesterol 
Fig. 6 Siglec‑E downregulates CD36‑mediated signaling. a WT peritoneal macrophages were treated with oxLDL (50 μg/ml) for indicated times. 
Cell lysates were prepared, followed by immunoprecipitation with anti‑Siglec E antibody. The immunoprecipitates were then subjected to Western 
blot analysis with indicated antibodies and analyzed by densitometry. The value at zero time point was referred to 1. The quantitative data are 
mean ± SE of 3 independent experiments. *P < 0.05 vs zero time point. b WT and  SE−/− macrophages were treated with oxLDL (50 μg/ml) for 
indicated times, and the cell lysates were analyzed by Western blotting with anti‑phosphoVAV and VAV antibodies and analyzed by densitometry. 
The value at zero time point was referred to 1. The quantitative data are mean ± SE of 3 independent experiments. *P < 0.05 vs WT group at the 
same time point. c The cell lysates prepared from WT and  SE−/− macrophages treated with oxLDL for indicated times as described above were 
subjected to immunoprecipitation with anti‑VAV antibody. The immunoprecipitates were subjected to Western blot analysis with indicated 
antibodies and analyzed by densitometry. The value at zero time point was referred to 1. The quantitative data showing relative SHP‑1/VAV are 
mean ± SE of 3 independent experiments. *P < 0.05 vs WT group at the same time point. d WT and  SE−/− macrophages were pretreated with 10 µM 
of NSC87877 for 30 min in culture, followed by incubation with Dil‑oxLDL (10 μg/ml) for another 1 h. The accumulation of intracellular Dil‑oxLDL 
was examined by confocal microscopy. e The quantitative results of (d). Data shown are the mean ± SE of 3 independent experiments. *P < 0.05 vs 
untreated WT cells; ƗP < 0.05 vs untreated WT cells
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accumulation in macrophages. Besides, sialic acids 
expressed on the surface of leukocytes play vital roles in 
cell recognition and adhesion, cell–cell interaction and 
signal transduction [29]. Siglecs are widely expressed 
on cells of immune system and modulate immune func-
tions via sialic acid-Siglec axis [5]. It has been shown that 
the expression of Siglec-1, which lacks the ITIM motifs 
observed in many Siglecs, is increased on circulating 
monocytes and correlated with the severity of coronary 
artery disease in human patients [29]. Down regula-
tion of Siglec-1 reduces oxLDL uptake in macrophages 
in  vitro and attenuates atherosclerosis in  apoE−/− mice 
[30]. A recent study also showed that Siglec-G expression 
on B-1 cells promotes atherosclerosis through inhibiting 
the production of oxLDL-specific IgM, which blocks the 
uptake of oxLDL by macrophages [31]. Whether other 
Siglecs have roles in the pathogenesis of atherosclerosis 
warrants further investigation.
In the present study, we showed that Siglec-E defi-
ciency accelerates lesion formation and plaque vulner-
ability in  apoE−/− mice. Foam cell formation and the 
inflammatory response were significantly enhanced in 
macrophages isolated from  apoE−/−/SE−/− mice com-
pared to  apoE−/− mice. We further demonstrated that 
Siglec-E expression suppressed modified LDL uptake 
but not cholesterol efflux in macrophages. Siglec-medi-
ated inhibition on cellular uptake was also observed for 
CD33 (Siglec-3) which inhibits uptake and clearance of 
amyloid beta 42 by microglia and is implicated in exac-
erbation of Alzheimer’s disease [32, 33]. To explore the 
molecular details how Siglec-E impacts modified LDL 
uptake, we conducted SILAC in conjunction with prox-
imity labeling to identify CD36 as a potential Siglec-E 
ligand. CD36 is a highly glycosylated protein expressed 
on macrophages to mediate modified LDL uptake [34]. 
We confirmed the interaction between SE and CD36 in 
HEK293T cells overexpressing these two proteins and 
in macrophages as well. A recent study by Kawecki et al. 
demonstrated that membrane neuraminidase 1 (NEU1) 
interacts with CD36 to modulate its sialylation level and 
oxLDL uptake in macrophages [35]. Consistent with their 
report, we found that CD36 is predominantly modified 
by α 2, 6-linked sialylation. Interestingly, sialic acid was 
not involved in the interaction between CD36 and Siglec-
E. A similar phenomenon has been reported for CD22/
Siglec-2 which interacts with CD45 and surface IgM 
independent of surface sialylation on B cells [36]. Never-
theless, sialic acid binding is essential for CD22 function 
as a negative regulator of B cell receptor signaling [37, 
38]. To explore whether Siglec-E-mediated inhibition of 
modified LDL uptake by CD36 requires sialic acid bind-
ing, we performed further experiments to compare Dil-
oxLDL uptake in HEK293T cells overexpressing WT and 
mutant Siglec-E together with CD36. Similar to previous 
findings by others [39, 40], CD36 expression alone pro-
motes Dil-oxLDL uptake in HEK293T cells. We showed 
that the extent of intracellular Dil-oxLDL accumulation 
was significantly reduced by coexpression of WT but 
not mutant Siglec-E lacking sialic acid binding activ-
ity. Notably, sialidase treatment significantly enhanced 
the uptake of Dil-oxLDL in CD36-expressing HEK293T 
cells regardless of whether WT or mutant Siglec-E was 
coexpressed. Sialidase treatment not only affected the 
availability of sialoglycan ligands required for Siglec-E 
activation, it also caused desialylation of CD36 which has 
been shown to increase CD36-mediated oxLDL uptake 
[35]. Under this condition, it is conceivable that the coex-
pression of Siglec-E would not have significant impact 
on the enhanced oxLDL uptake-mediated by CD36. We 
also observed the promoting effect of desialylation on 
oxLDL uptake in macrophages. These findings highlight 
the importance of cell surface sialylation status on foam 
cell formation. OxLDL failed to bind and induce tyrosine 
phosphorylation of Siglec-E expressed alone in HEK293T 
cells, indicating that oxLDL does not serve as a ligand 
for Siglec-E. Whereas it promoted WT but not mutant 
Siglec-E phosphorylation in cells coexpressing CD36. 
Likewise, desialylation abolished oxLDL-induced Siglec-
E phosphorylation in macrophages. These observa-
tions suggest that the binding of Siglec-E with a putative 
sialoglycan ligand presented on a surface protein, which 
is likely recruited and complexed with oxLDL-bound 
CD36, is vital to elicit Siglec-E activation as depicted in 
Fig.  7. Further studies are needed to address this possi-
bility. Interestingly, we noticed there was an increase in 
the basal phosphorylation of Siglec-E in cells coexpress-
ing CD36 even without oxLDL treatment. Since CD36 
is known to bind many different ligands, including fatty 
acids and other substances in serum [41], it is likely that 
CD36 can be activated by serum present in the culture 
medium, resulting in the recruitment of the putative 
sialoglycan ligand and subsequent Siglec-E phosphoryla-
tion to certain extent in the absence of oxLDL. Notably, 
CD36 coexpression also induced a modest phosphoryla-
tion of mutant Siglec-E, which is much less than that of 
WT Siglec-E. We speculate that the activation of Lyn/Fyn 
tyrosine kinase following oxLDL-CD36 interaction would 
also promote phosphorylation of ITIM motifs of Siglec-E 
to certain degree irrespective of binding with sialoglycan 
ligand.
It is documented that phosphorylation of VAV follow-
ing oxLDL binding with CD36 transactivates the down-
stream small G proteins such as rac/rho and dynamin to 
mediate the endocytosis of oxLDL [20, 21]. Previous stud-
ies have shown that SHP-1-mediated VAV dephospho-
rylation takes part in FAS-mediated cell death signaling 
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in B cells [42] and inhibition of NK cell-mediated cellular 
cytotoxicity [43]. Therefore, to further understand how 
Siglec-E affects CD36-mediated oxLDL uptake in mac-
rophages, we explored the potential impact of Siglec-E/
SHP-1 axis on VAV phosphorylation. Co-immunoprecip-
itation experiment demonstrated that oxLDL treatment 
induced a transient recruitment of SHP-1 by Siglec-E in 
macrophages, indicating the activation of Siglec-E/SHP-1 
axis by oxLDL. Moreover, oxLDL induced a transient 
interaction between SHP-1 and VAV, which was more 
prominent in WT macrophages comparing to  SE−/− 
counterparts. Concurrently, the level of VAV phosphoryl-
ation following oxLDL treatment was substantially lower 
in WT macrophages. The impact of SHP-1 on the modu-
lation of oxLDL uptake was further demonstrated by the 
experiment showing that SHP-1 inhibition significantly 
increased Dil-oxLDL uptake in WT macrophages but 
not in  SE−/− macrophages. Collectively, these findings 
support the significance of crosstalk between Siglec-E 
and CD36 signalings in the regulation of CD36-mediated 
oxLDL uptake and foam cell formation.
Conclusions
The present study provides both in  vitro and in  vivo 
evidence to demonstrate the inhibitory function of 
Siglec-E in the regulation of foam cell formation in the 
course of atherosclerosis. Although sialic acid is not 
required for the physical interaction of Siglec-E with 
CD36, it is pivotal for eliciting Siglec-E negative sign-
aling following oxLDL binding with CD36. A previous 
study has shown that NEU1 is highly expressed in the 
macrophages of human atherosclerotic plaques [44]. It 
is conceivable that the increased desialylation would 
result in the exacerbation of the uptake and accumula-
tion of cholesterol and inflammatory response in mac-
rophages. A recent study has shown that nanoparticles 
decorated with sialic acids are effective in promoting 
Siglec-E-mediated anti-inflammatory response and 
abrogate sepsis and acute respiratory distress syn-
drome in animals [45]. Whether similar approach can 
be taken to augment the activation of Siglec-E/SHP-1 
axis to ameliorate atherosclerosis warrants further 
investigation.
Fig. 7 Schematic diagram illustrating Siglec‑E‑induced negative signaling on CD36‑mediated oxLDL uptake on macrophages. Siglec‑E physically 
interacts with CD36 through their polypeptides in resting state. When oxLDL binds to CD36, oxLDL‑CD36 complex elicits the recruitment of a 
putative surface protein containing sialoglycan to interact with Siglec‑E and activate Siglec‑E/SHP‑1 axis, which in turn inhibits CD36 downstream 
signaling for oxLDL uptake
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